Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1955 1
2005 1
2007 2
2013 1
2015 1
2016 3
2017 1
2018 1
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Results by year
Filters applied: . Clear all
Page 1
A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the "Metabolites in Safety Testing" Regulatory Guidance.
Schadt S, Bister B, Chowdhury SK, Funk C, Hop CECA, Humphreys WG, Igarashi F, James AD, Kagan M, Khojasteh SC, Nedderman ANR, Prakash C, Runge F, Scheible H, Spracklin DK, Swart P, Tse S, Yuan J, Obach RS. Schadt S, et al. Among authors: Scheible H. Drug Metab Dispos. 2018 Jun;46(6):865-878. doi: 10.1124/dmd.117.079848. Epub 2018 Feb 27. Drug Metab Dispos. 2018. PMID: 29487142 Review.
In vitro and in vivo drug disposition of cilengitide in animals and human.
Dolgos H, Freisleben A, Wimmer E, Scheible H, Krätzer F, Yamagata T, Gallemann D, Fluck M. Dolgos H, et al. Among authors: Scheible H. Pharmacol Res Perspect. 2016 Mar 17;4(2):e00217. doi: 10.1002/prp2.217. eCollection 2016 Apr. Pharmacol Res Perspect. 2016. PMID: 27069630 Free PMC article.
Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.
von Richter O, Massimini G, Scheible H, Udvaros I, Johne A. von Richter O, et al. Among authors: Scheible H. Br J Clin Pharmacol. 2016 Dec;82(6):1498-1508. doi: 10.1111/bcp.13078. Epub 2016 Sep 19. Br J Clin Pharmacol. 2016. PMID: 27483391 Free PMC article. Clinical Trial.
Pharmacokinetics of ML3403 ({4-[5-(4-fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-Pyridinylimidazole-type p38 mitogen-activated protein kinase inhibitor.
Kammerer B, Scheible H, Albrecht W, Gleiter CH, Laufer S. Kammerer B, et al. Among authors: Scheible H. Drug Metab Dispos. 2007 Jun;35(6):875-83. doi: 10.1124/dmd.106.013409. Epub 2007 Mar 7. Drug Metab Dispos. 2007. PMID: 17344341
Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers.
Johne A, Scheible H, Becker A, van Lier JJ, Wolna P, Meyring M. Johne A, et al. Among authors: Scheible H. Invest New Drugs. 2020 Mar 27. doi: 10.1007/s10637-020-00926-1. Online ahead of print. Invest New Drugs. 2020. PMID: 32221754
13 results
Jump to page
Feedback